Psychiatric Times
JUNE 25, 2025
Knoll IV, MD November 19th 2024 4 Ways to Cope With Bipolar Uncertainty James Phelps, MD September 19th 2024 Borderline Personality Disorder and Complex Posttraumatic Stress Disorder: Myths in Diagnosis Mark L.
Psychiatric Times
JULY 8, 2025
An sNDA for Caplyta as an adjunctive treatment for adults with major depressive disorder (MDD) is also currently under FDA review, submitted back in December 2024. sNDA submitted: lumateperone as adjunctive therapy for major depressive disorder. December 3, 2024. points (effect size 0.61) in study 501 and 4.5
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
AUGUST 1, 2025
Example articles include: ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment ADHD: Overlooked Cause of Persistent Anxiety and Depression in Adults Childhood Physical Health and ADHD Symptoms Longitudinal Study Looks at Risk of Cardiovascular Disease With Long-Term ADHD Medication Use References 1.
Psychiatric Times
JULY 22, 2025
August 9, 2024. September 11, 2024. Suicide risk in people with post-traumatic stress disorder: a cohort study of 3.1 but in what areas can we improve treatment outcomes and real-world functioning for patients with PTSD? but in what areas can we improve treatment outcomes and real-world functioning for patients with PTSD?
Psychiatric Times
JULY 22, 2025
October 19, 2024. September 3, 2024. October 19, 2024. June 25, 2024. March 18, 2024. Gaslighting, narcissist, and more psychology terms you're misusing. March 15, 2023. Accessed April 10, 2025. When therapy goes wrong: the problem of underqualified psychotherapists. The Guardian. Accessed July 8, 2025.
Psychiatric Times
JULY 7, 2025
Additionally, Vanda initiated a phase 3 clinical study for Bysanti as a once-daily adjunctive treatment for major depressive disorder in the fourth quarter of 2024. If approved, Bysanti could be available for sale in the US in 2026. Results are expected in 2026.
Psychiatric Times
JULY 29, 2025
A phase 3, dose-optimized, double-blind, randomized, placebo controlled, single-center, parallel efficacy and safety laboratory classroom study in adults with attention-deficit/hyperactivity disorder (ADHD) using CTx-1301 (dexmethylphenidate): effect size assessment. Accessed May 21, 2024. Poster presentation. News release.
Expert insights. Personalized for you.
Let's personalize your content